Excited to announce that FaunaBio and Eli Lilly and Company have announced a strategic collaboration to discover novel #obesity targets using its #Convergence AI platform in a deal worth up to $494M. 🚀🚀🚀 Fauna's Convergence™ AI platform analyzes data collected from the protective adaptations of hibernation biology (and other extreme adaptations) to identify drug targets for humans. Fauna identifies the best genes to target for efficacy in diseases with high unmet need and can identify genes to target within a broad range of treatment modalities. "We are very excited to enter into this collaboration with Lilly, which showcases the power of our Convergence™ AI platform to rapidly identify novel targets for complex disease areas of high unmet need," said Ashley Zehnder, CEO & Co-Founder, Fauna Bio. "Lilly is a leader in obesity treatment, and our approach enables and accelerates discovery across different disease areas and modalities for our partners, who bring deep expertise in drug development." Read the full release: 👇👇👇 https://lnkd.in/eXKDEKze
congrats Ashley Zehnder and Fauna team!
CEO, co-founder at Meliora Therapeutics
9mocongrats Ashley Zehnder!